Greenberg Lecture: Restoration of the Microbiome in Disease Control
* You will be redirected to the BCM DCPD credit management site when claiming credit and may be asked to register or log in.
In this inaugural Stephen B. Greenberg Lecture, Dr. Herbert L. DuPont discusses the microbiota-gut-brain axis and the importance of identifying and maintaining a healthy microbiome. He highlights how the microbiome can influence disease states such as recurrent C. difficile infections, Parkinson's Disease, and cancer and adverse events from immunotherapy.
This Department of Medicine Grand Rounds session will take place on Thursday, November 17, 2022 at 12:15 p.m. Attendance will be available in-person in the DeBakey Building, Room M.112; and virtually through Zoom.
Activity Information
How to Claim Credit
You may claim credit after watching this activity.
You will be redirected to the BCM DCPD credit management site when claiming credit and may be asked to register or log in.
Needs Statement
Faculty and trainees within the Department of Medicine who are involved in the care of patients need to receive regular updates on recent advances and guidelines in the field of internal medicine. Clinical scenarios will be used to review the current management of common medical conditions, including chronic pain and opioid abuse. Multidisciplinary sessions will be also used to educate learners about human trafficking and the role of physicians in identifying and assisting victims in the community. The overall aim of the series is to advance clinical knowledge, enhance the quality of patient care, and improve treatment outcomes.
Educational Objectives
At the conclusion of the session, the participants should be able to:
- Describe the three general pathways by which the gut microbiota and the gut communicate with the brain (microbiome-gut-brain axis).
- Define a healthy and an unhealthy (dysbiotic) microbiome.
- Name two objectives of treatment for Clostridioides difficile infection that shorten illness and prevent recurrence.
- Discuss the role of the microbiome in efficacy of checkpoint inhibitor immunotherapy for treatment of cancer and the potential role of fecal microbiota transplantation (FMT) in the treatment of immune colitis.
Target Audience
Professional Categories
- Physicians
- Medical Students
- Fellows
- Residents
Specialties
- Internal Medicine
Interest Groups
- Hospital Medicine
Activity Evaluation
Evaluation by questionnaire will address program content, presentation, and possible bias.
Educational Methods
- Lectures
Accreditation/Credit Designation
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this enduring material activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Activity Director
Term of Approval
November 1, 2022 through November 30, 2024. Original release date: November 1, 2022.
Disclosure Policy
Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.
In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.
In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.
BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:
Presenter
-
Herbert L. DuPont, M.D., MACP
Mary W. Kelsey Chair of Medical Sciences, Professor of Infectious Diseases and Epidemiology
UT McGovern Medical School, UT School of Public Health
Disclosure:
Nothing to disclose.
Activity Director
Planning Committee Members
-
-
Richard J. Hamill, M.D.
Professor
Baylor College of Medicine
Disclosure:
- Advisory Committee Membership: Moderna TX, Inc. (Chair, Adjudication Committee)
-
Kristen Lavere, M.D.
Internal Medicine Resident
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Zaven Sargsayan, M.D.
Assistant Professor
Baylor College of Medicine and Ben Taub Hospital
Disclosure:
Nothing to disclose.
-
Stephanie Sherman, M.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Health Topics
Presenter: